Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.
Also called NCT06005259
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 264 participants
- Sponsor
- Registry
-
NCT06005259
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Unknown status
Technical summary
Registry record NCT06005259. Randomized; triple masking; primary purpose prevention. Start 2023-10-01 (anticipated); primary completion 2025-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
- Acronym
- SPIROTOX
- Condition
- Cardiotoxicity
- Condition
- Neoplasms
- Condition
- Chemotherapy Effect
- Condition
- Heart Failure
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Sao Paulo
Record details
- Record id
cardio:ct-nct06005259- Content hash
24aa5f63e7b350f0f0e6f0e41aca42129ae6fe8cf148d722334bd7cd991a5271